Matthew Yan
Stock Analyst at CLSA
(3.97)
# 1,820
Out of 4,692 analysts
45
Total ratings
63.4%
Success rate
15.4%
Average return
Main Sectors:
Stocks Rated by Matthew Yan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HKG: 9995 RemeGen Co., Ltd. | Maintained: Buy | $136.90 → $144.80 | $80.70 | +79.43% | 6 | Aug 25, 2026 | |
| HKG: 1801 Innovent Biologics, Inc. | Maintained: Buy | $120.10 | $103.80 | +15.70% | 17 | Dec 8, 2025 | |
| HKG: 6160 BeOne Medicines AG | Maintained: Buy | $264.40 → $288.00 | $215.40 | +33.70% | 10 | Nov 7, 2025 | |
| HKG: 6990 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Maintained: Buy | $548.60 | $497.20 | +10.34% | 3 | Oct 19, 2025 | |
| HKG: 9606 Duality Biotherapeutics, Inc. | Initiated Coverage: Buy | $268.30 | $184.30 | n/a | 1 | May 22, 2025 | |
| ONC BeOne Medicines AG | Maintained: Buy | $270 → $263 | $359.58 | n/a | 3 | Nov 13, 2024 | |
| TYO: 4568 Daiichi Sankyo Company, Limited | Maintained: Buy | ¥6,800 → ¥7,000 | ¥2,879 | n/a | 4 | Oct 31, 2024 | |
| HKG: 0013 HUTCHMED (China) Limited | Maintained: Buy | $41.41 | $19.37 | n/a | 1 | Aug 3, 2023 |
RemeGen Co., Ltd.
Aug 25, 2026
Maintained: Buy
Price Target: $136.90 → $144.80
Current: $80.70
Upside: +79.43%
Innovent Biologics, Inc.
Dec 8, 2025
Maintained: Buy
Price Target: $120.10
Current: $103.80
Upside: +15.70%
BeOne Medicines AG
Nov 7, 2025
Maintained: Buy
Price Target: $264.40 → $288.00
Current: $215.40
Upside: +33.70%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025
Maintained: Buy
Price Target: $548.60
Current: $497.20
Upside: +10.34%
Duality Biotherapeutics, Inc.
May 22, 2025
Initiated Coverage: Buy
Price Target: $268.30
Current: $184.30
Upside: n/a
BeOne Medicines AG
Nov 13, 2024
Maintained: Buy
Price Target: $270 → $263
Current: $359.58
Upside: n/a
Daiichi Sankyo Company, Limited
Oct 31, 2024
Maintained: Buy
Price Target: ¥6,800 → ¥7,000
Current: ¥2,879
Upside: n/a
HUTCHMED (China) Limited
Aug 3, 2023
Maintained: Buy
Price Target: $41.41
Current: $19.37
Upside: n/a